GlassScriptPhysician profile
Edmundo R Rubio
NPI 1619073491
$9,571.13
in general payments reported to CMS, 2019-2025
9 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,413 · 2021: $11.56 · 2023: $124 · 2024: $7,877 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,000 · Travel and Lodging: $844 · Food and Beverage: $270 · Grant: $32.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,000.00 |
| Travel and Lodging | $844.31 |
| Food and Beverage | $269.72 |
| Grant | $32.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,844.31 | 2024 | |
| Pulmonx Corporation | $985.39 | 2019 | |
| Genentech USA, INC. | $223.53 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $186.81 | 2019 | |
| Madrigal Pharmaceuticals | $145.39 | 2025 | Rezdiffra |
| Olympus America INC. | $124.33 | 2023 | Spin Perc Localization Needle 19ga X 105mm, 1cm Marking Zone, Always-On Tip Tracked Forceps, 1.8mm Od, Serrated Cup |
| Cook Incorporated | $32.43 | 2024 | |
| Covidien LP | $17.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmundo Rubio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.